Associate Professor of Medicine, Harvard Medical School
Internal Medicine
Dr. Raymond T. Chung, MD
|
|
Give Review
Raymond T. Chung practices Internal Medicine. He graduated from Yale University School of Medicine. Yale University School of Medicine is one of the top medical schools in the US. Yale University School of Medicine is ranked 7/57 in Research/PrimaryCare. He has 1 awards "America's Top Doctors". Raymond T. Chung is a published doctor. He published 101 publications, including: 'Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis.' Raymond Chung accepts Medicare payments and is listed with Medicare.gov.
Publications
- Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of Cirrhosis.
- Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis.
- Diabetes and prediabetes in patients with hepatitis B residing in North America.
- Enhancing our understanding of current therapies for hepatitis C virus (HCV).
- HBV infection is associated with greater mortality in hospitalised patients compared to HCV infection or alcoholic liver Disease.
- Coagulation and fibrosis: a potential non-negligible target of statins in chronic hepatitis.
- Reduced Albumin Dosing During Large-Volume Paracentesis Is Not Associated with Adverse Clinical Outcomes.
- Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C.
- Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
- The spliceosome factor SART1 exerts its anti-HCV action through mRNA splicing.
- The effect of hepatitis C virologic clearance on cardiovascular Disease biomarkers in human immunodeficiency virus/hepatitis C virus coinfection.
- Optimal antiviral prophylaxis against hepatitis B reactivation in patients receiving rituximab-based chemotherapy for lymphoma.
- Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions.
- Shear-Wave Elastography for the Estimation of Liver Fibrosis in Chronic Liver Disease: Determining Accuracy and Ideal Site for Measurement.
- Hepatitis C Virus-Associated Cancer.
- Hepatitis C virus NS5A Drives a PTEN-PI3K/Akt Feedback Loop to Support Cell Survival.
- Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma.
- Correlates of Adiponectin in Hepatitis C Infected Children: The Importance of Body Mass Index.
- A genomic and clinical prognostic index for hepatitis C-related early-stage Cirrhosis that predicts clinical deterioration.
- B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related Disease.
- 2-year outcomes in Initial survivors with Acute Liver failure: Results from a Prospective, Multicenter Study.
- Poor Adherence to AASLD Guidelines for Chronic Hepatitis B Management and Treatment in a Large Academic Medical Center.
- Widespread Morbilliform Eruption Associated With Telaprevir: Use of Dermatologic Consultation to Increase Tolerability.
- Curing Chronic Hepatitis C - The Arc of a Medical Triumph.
- Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma.
- Hepatitis C treatment: an incipient therapeutic revolution.
- Admixture analysis of spontaneous hepatitis C virus clearance in individuals of African descent.
- Lamivudine compared with newer antivirals for prophylaxis of hepatitis B core antibody positive livers: a cost-effectiveness analysis.
- Pilot Study of Pioglitazone Before HCV Retreatment in HIV/HCV Genotype 1-Infected Subjects With Insulin Resistance and Previous Nonresponse to Peginterferon and Ribavi...
- Entry inhibitors and future treatment of hepatitis C.
- HCV and HIV co-infection: mechanisms and management.
- After the Cure: Management of HCV After Achievement of SVR.
- Circulating mitochondrial DNA in patients in the ICU as a marker of mortality: derivation and validation.
- HCV and host lipids: an intimate connection.
- Pharmacological Inhibition of a MicroRNA Family in Nonhuman Primates by a Seed-Targeting 8-Mer AntimiR.
- Liver Environment and HCV Replication Affect Human T-Cell Phenotype and Expression of Inhibitory Receptors.
- In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated ...
- Kinetic differences in the induction of interferon stimulated genes by interferon-α and IL28B are altered by Infection with Hepatitis C virus.
- Advanced Disease, Diuretic Use, and Marital Status Predict Hospital Admissions in an Ambulatory Cirrhosis Cohort.
- Prophylaxis of hepatitis B infection in solid organ transplant recipients.
- The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-β signaling.
- Direct Acting Antiviral Agents and the Path to Interferon Independence.
- Human immunodeficiency virus and liver Disease forum 2012.
- One more piece in the interleukin 28B gene puzzle? The case of hepatitis B.
- Pathogenesis of Accelerated Fibrosis in HIV/HCV Co-infection.
- A Genetic Screen Identifies Interferon-? Effector Genes Required to Suppress Hepatitis C Virus Replication.
- IL28B Testing in a Rapidly Changing World: Still Relevant?
- A TALEN Genome-Editing System for Generating Human Stem Cell-Based Disease Models.
- Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts.
- Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study.
- Prognostic Gene-Expression Signature for Patients with Hepatitis C-Related Early-Stage Cirrhosis.
- SOCS1 Abrogates IFN's Antiviral Effect on Hepatitis C Virus Replication: SOCS1 inhibit the anti-HCV effect of IFN.
- Future classes of hepatitis C virus therapeutic agents.
- The Double-edged Sword of Functional Liver Imaging.
- Development of an Accurate Index for Predicting Outcomes of Patients with Acute Liver Failure.
- Pathogenesis of Liver Injury in Acute Liver Failure: Meeting Summary.
- HCV NS5A disrupts STAT1 phosphorylation and suppresses type I IFN signaling.
- Anti-hepatitis C virus drugs in development.
- Lipid Metabolite Profiling Identifies Desmosterol Metabolism as a New Antiviral Target for Hepatitis C Virus.
- A watershed moment in the treatment of hepatitis C.
- Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence.
- The impact of human gene polymorphisms on HCV infection and Disease outcome.
- Short and Long-Term Outcomes in Patients with Acute Liver Failure Due to Ischemic Hepatitis.
- Human immunodeficiency virus and liver Disease forum 2010: Conference proceedings.
- A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virus.
- Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme a synthase.
- Hepatocellular Carcinoma Screening Rates Vary by Etiology of Cirrhosis and Involvement of Gastrointestinal Sub-specialists.
- Adding to the Toolbox: Receptor Tyrosine Kinases as Potential Targets in the Treatment of Hepatitis C.
- Pretransplant depression, antidepressant use, and outcomes of orthotopic liver transplantation.
- Can we use the "C" word with confidence? Cure for chronic hepatitis C.
- Naringenin Inhibits the Assembly and Long-Term Production of Infectious Hepatitis C Virus Particles Through a PPAR-Mediated Mechanism.
- Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes.
- The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort.
- HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB.
- Novel Therapies for Hepatitis C: Insights from the Structure of the Virus.
- New protease inhibitors for HCV - Help is on the way.
- IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway.
- Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C.
- A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients.
- Generation of human induced pluripotent stem cells from liver progenitor cells by only small molecules.
- Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection.
- High antibody level: an accurate serologic marker of viremia in asymptomatic people with hepatitis C infection.
- Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner.
- Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner.
- Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop.
- Reaping the early harvest of the genomics revolution.
- An identification of novel therapy for human hepatocellular carcinoma by using human induced pluripotent stem cells.
- An indicator for evaluating the risk of Cancerous transformations of human induced pluripotent stem cells.
- Tumorigenicity of human induced pluripotent stem cells depends on the balance of gene expression between p21 and p53.
- Human immunodeficiency virus and liver Disease: conference proceedings.
- New translational research on novel drugs for hepatitis C virus 1b infection by using a replicon System and human induced pluripotent stem cells.
- An identification of the novel combination therapy for hepatitis C virus 1b infection by using a replicon System and human induced pluripotent stem cells.
- When treating Cancer, please don't forget hepatitis B.
- Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up.
- IgG4-associated cholangitis: a comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material.
- Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers.
- Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria.
- Changes in Kidney Function After Transjugular Intrahepatic PortoSystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis.
- Safety and Efficacy of Sofosbuvir-Containing Regimens in Hepatitis C Infected Patients with Impaired Renal Function.
- Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.
Schools
Yale University School Of Medicine
Johns Hopkins Hospital
Massachusetts General Hospital
Procedures Preformed
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
- Liver Biopsy
Conditions Treated
- Abdominal Pain
- Anemia
- Barrett's Esophagus
- Benign Neoplasm of the Digestive System
- View All
Doctors Specialties
- Gastroenterology
- Transplant Hepatology
- Internal Medicine
Accepted Insurances
Awards
- America's Top Doctors
Education
-
Massachusetts General Hospital -
Johns Hopkins University -
Yale University School of Medicine
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1154311769 | |
| NPPES Provider LastName | CHUNG | |
| NPPES Provider FirstName | RAYMOND | |
| NPPES Provider ZIPCode | 021142696 | |
| NPPES Provider State | MA | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 318.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1154311769 |
| Last Name Of The Provider | CHUNG |
| First Name Of The Provider | RAYMOND |
| View All |
Similar Doctors
|
|
Dr. Julia Y. McNabb-Baltar, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Norman D. Grace, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Allison R. Schulman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lindsey T. Surace, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joanna M. Peloquin, MD |
|
|
Dr. Jacqueline L. Wolf, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gail H. Kaufman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chana A. Sacks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kiran C. Reddy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter V. Tishler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yusuf Konuk, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michelle L. Hughes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rong J. Guan, MD
This Doctor is OpenDoctor Recommended.
|